The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)

Eric Van Cutsem

Digestive Oncology Unit

University Hospital Gasthuisberg

3000 Leuven



Name/email consistency: high



  • Digestive Oncology Unit, University Hospital Gasthuisberg, 3000 Leuven, Belgium. 2012 - 2013
  • University Hospital Gasthuisberg, Digestive Oncology Unit, Herestraat 49, 3000 Leuven, Belgium;. 1999 - 2012


  1. Phase I dose-escalation study of intravenous aflibercept administered in combination with irinotecan, 5-fluorouracil and leucovorin in patients with advanced solid tumours. Van Cutsem, E., Khayat, D., Verslype, C., Billemont, B., Tejpar, S., Meric, J.B., Soussan-Lazard, K., Assadourian, S., Cartot-Cotton, S., Rixe, O. Eur. J. Cancer (2013) [Pubmed]
  2. Addition of Aflibercept to Fluorouracil, Leucovorin, and Irinotecan Improves Survival in a Phase III Randomized Trial in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen. Van Cutsem, E., Tabernero, J., Lakomy, R., Prenen, H., Prausová, J., Macarulla, T., Ruff, P., van Hazel, G.A., Moiseyenko, V., Ferry, D., McKendrick, J., Polikoff, J., Tellier, A., Castan, R., Allegra, C. J. Clin. Oncol. (2012) [Pubmed]
  3. Intrapatient cetuximab dose escalation in metastatic colorectal cancer according to the grade of early skin reactions: the randomized EVEREST study. Van Cutsem, E., Tejpar, S., Vanbeckevoort, D., Peeters, M., Humblet, Y., Gelderblom, H., Vermorken, J.B., Viret, F., Glimelius, B., Gallerani, E., Hendlisz, A., Cats, A., Moehler, M., Sagaert, X., Vlassak, S., Schlichting, M., Ciardiello, F. J. Clin. Oncol. (2012) [Pubmed]
  4. Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor KRAS and BRAF Mutation Status. Van Cutsem, E., Köhne, C.H., Láng, I., Folprecht, G., Nowacki, M.P., Cascinu, S., Shchepotin, I., Maurel, J., Cunningham, D., Tejpar, S., Schlichting, M., Zubel, A., Celik, I., Rougier, P., Ciardiello, F. J. Clin. Oncol. (2011) [Pubmed]
  5. Randomized, Placebo-Controlled, Phase III Study of Oxaliplatin, Fluorouracil, and Leucovorin With or Without PTK787/ZK 222584 in Patients With Previously Treated Metastatic Colorectal Adenocarcinoma. Van Cutsem, E., Bajetta, E., Valle, J., Köhne, C.H., Randolph Hecht, J., Moore, M., Germond, C., Berg, W., Chen, B.L., Jalava, T., Lebwohl, D., Meinhardt, G., Laurent, D., Lin, E. J. Clin. Oncol. (2011) [Pubmed]
  6. Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study. Van Cutsem, E., Rivera, F., Berry, S., Kretzschmar, A., Michael, M., DiBartolomeo, M., Mazier, M.A., Canon, J.L., Georgoulias, V., Peeters, M., Bridgewater, J., Cunningham, D. Ann. Oncol. (2009) [Pubmed]
  7. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. Van Cutsem, E., Köhne, C.H., Hitre, E., Zaluski, J., Chang Chien, C.R., Makhson, A., D'Haens, G., Pintér, T., Lim, R., Bodoky, G., Roh, J.K., Folprecht, G., Ruff, P., Stroh, C., Tejpar, S., Schlichting, M., Nippgen, J., Rougier, P. N. Engl. J. Med. (2009) [Pubmed]
  8. Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3. Van Cutsem, E., Labianca, R., Bodoky, G., Barone, C., Aranda, E., Nordlinger, B., Topham, C., Tabernero, J., André, T., Sobrero, A.F., Mini, E., Greil, R., Di Costanzo, F., Collette, L., Cisar, L., Zhang, X., Khayat, D., Bokemeyer, C., Roth, A.D., Cunningham, D. J. Clin. Oncol. (2009) [Pubmed]
  9. Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. Van Cutsem, E., Vervenne, W.L., Bennouna, J., Humblet, Y., Gill, S., Van Laethem, J.L., Verslype, C., Scheithauer, W., Shang, A., Cosaert, J., Moore, M.J. J. Clin. Oncol. (2009) [Pubmed]
  10. A phase Ib dose-escalation study of erlotinib, capecitabine and oxaliplatin in metastatic colorectal cancer patients. Van Cutsem, E., Verslype, C., Beale, P., Clarke, S., Bugat, R., Rakhit, A., Fettner, S.H., Brennscheidt, U., Feyereislova, A., Delord, J.P. Ann. Oncol. (2008) [Pubmed]
  11. Expert opinion on management of gastric and gastro-oesophageal junction adenocarcinoma on behalf of the European Organisation for Research and Treatment of Cancer (EORTC)-gastrointestinal cancer group. Van Cutsem, E., Van de Velde, C., Roth, A., Lordick, F., Köhne, C.H., Cascinu, S., Aapro, M. Eur. J. Cancer (2008) [Pubmed]
  12. The diagnosis and management of rectal cancer: expert discussion and recommendations derived from the 9th World Congress on Gastrointestinal Cancer, Barcelona, 2007. Van Cutsem, E., Dicato, M., Haustermans, K., Arber, N., Bosset, J.F., Cunningham, D., De Gramont, A., Diaz-Rubio, E., Ducreux, M., Goldberg, R., Glynne-Jones, R., Haller, D., Kang, Y.K., Kerr, D., Labianca, R., Minsky, B.D., Moore, M., Nordlinger, B., Rougier, P., Scheithauer, W., Schmoll, H.J., Sobrero, A., Tabernero, J., Tempero, M., Van de Velde, C., Zalcberg, J. Ann. Oncol. (2008) [Pubmed]
  13. Optimizing administration of epidermal growth factor receptor-targeted agents in the treatment of colorectal cancer. Van Cutsem, E. Clin. Colorectal. Cancer (2007) [Pubmed]
  14. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. Van Cutsem, E., Peeters, M., Siena, S., Humblet, Y., Hendlisz, A., Neyns, B., Canon, J.L., Van Laethem, J.L., Maurel, J., Richardson, G., Wolf, M., Amado, R.G. J. Clin. Oncol. (2007) [Pubmed]
  15. The multidisciplinary management of gastrointestinal cancer. The integration of cytotoxics and biologicals in the treatment of metastatic colorectal cancer. Van Cutsem, E., Geboes, K. Best. Pract. Res. Clin. Gastroenterol (2007) [Pubmed]
  16. The neo-adjuvant, surgical and adjuvant treatment of gastric adenocarcinoma. Current expert opinion derived from the Seventh World Congress on Gastrointestinal Cancer, Barcelona, 2005. Van Cutsem, E., Dicato, M., Arber, N., Benson, A., Cunningham, D., Diaz-Rubio, E., Glimelius, B., Goldberg, R., Haller, D., Haustermans, K., Koo-Kang, Y., Labianca, R., Lang, I., Minsky, B., Nordlinger, B., Roth, A., Rougier, P., Schmoll, H.J., Sobrero, A., Tabernero, J., Szawlowski, A., van de Velde, C. Ann. Oncol. (2006) [Pubmed]
  17. Challenges in the use of epidermal growth factor receptor inhibitors in colorectal cancer. Van Cutsem, E. Oncologist (2006) [Pubmed]
  18. Oral capecitabine: bridging the Atlantic divide in colon cancer treatment. Van Cutsem, E., Verslype, C., Tejpar, S. Semin. Oncol. (2005) [Pubmed]
  19. Optimisation of irinotecan dose in the treatment of patients with metastatic colorectal cancer after 5-FU failure: results from a multinational, randomised phase II study. Van Cutsem, E., Dirix, L., Van Laethem, J.L., Van Belle, S., Borner, M., Gonzalez Baron, M., Roth, A., Morant, R., Joosens, E., Gruia, G., Sibaud, D., Bleiberg, H. Br. J. Cancer (2005) [Pubmed]
  20. The causes and consequences of cancer-associated malnutrition. Van Cutsem, E., Arends, J. Eur. J. Oncol. Nurs (2005) [Pubmed]
  21. Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials. Van Cutsem, E., Hoff, P.M., Harper, P., Bukowski, R.M., Cunningham, D., Dufour, P., Graeven, U., Lokich, J., Madajewicz, S., Maroun, J.A., Marshall, J.L., Mitchell, E.P., Perez-Manga, G., Rougier, P., Schmiegel, W., Schoelmerich, J., Sobrero, A., Schilsky, R.L. Br. J. Cancer (2004) [Pubmed]
  22. Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. Van Cutsem, E., van de Velde, H., Karasek, P., Oettle, H., Vervenne, W.L., Szawlowski, A., Schoffski, P., Post, S., Verslype, C., Neumann, H., Safran, H., Humblet, Y., Perez Ruixo, J., Ma, Y., Von Hoff, D. J. Clin. Oncol. (2004) [Pubmed]
  23. The treatment of advanced gastric cancer: new findings on the activity of the taxanes. Van Cutsem, E. Oncologist (2004) [Pubmed]
  24. Systemic treatment of pancreatic cancer. Van Cutsem, E., Aerts, R., Haustermans, K., Topal, B., Van Steenbergen, W., Verslype, C. Eur. J. Gastroenterol. Hepatol (2004) [Pubmed]
  25. Can the addition of bevacizumab to IFL chemotherapy improve outcome in colorectal cancer?. Van Cutsem, E. Nature Clinical Practice. Gastroenterology & Hepatology (2004) [Pubmed]
  26. Raltitrexed: current clinical status and future directions. Van Cutsem, E., Cunningham, D., Maroun, J., Cervantes, A., Glimelius, B. Ann. Oncol. (2002) [Pubmed]
  27. Adjuvant treatment of colorectal cancer (current expert opinion derived from the Third International Conference: Perspectives in Colorectal Cancer, Dublin, 2001). Van Cutsem, E., Dicato, M., Wils, J., Cunningham, D., Diaz-Rubio, E., Glimelius, B., Haller, D., Johnston, P., Kerr, D., Koehne, C.H., Labianca, R., Minsky, B., Nordlinger, B., Roth, A., Rougier, P., Schmoll, H.J. Eur. J. Cancer (2002) [Pubmed]
  28. Thymidine phosphorylase (TP) activation: convenience through innovation. Van Cutsem, E., Cunningham, D., Hoff, P.M., Maroun, J. Oncologist (2001) [Pubmed]
  29. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. Van Cutsem, E., Twelves, C., Cassidy, J., Allman, D., Bajetta, E., Boyer, M., Bugat, R., Findlay, M., Frings, S., Jahn, M., McKendrick, J., Osterwalder, B., Perez-Manga, G., Rosso, R., Rougier, P., Schmiegel, W.H., Seitz, J.F., Thompson, P., Vieitez, J.M., Weitzel, C., Harper, P. J. Clin. Oncol. (2001) [Pubmed]
  30. Recent advances in the management of colorectal cancer. Van Cutsem, E., Dicato, M., Wils, J. Eur. J. Cancer (2001) [Pubmed]
  31. Capecitabine, an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer: results of a randomized phase II study. Van Cutsem, E., Findlay, M., Osterwalder, B., Kocha, W., Dalley, D., Pazdur, R., Cassidy, J., Dirix, L., Twelves, C., Allman, D., Seitz, J.F., Schölmerich, J., Burger, H.U., Verweij, J. J. Clin. Oncol. (2000) [Pubmed]
  32. Clinical activity and benefit of irinotecan (CPT-11) in patients with colorectal cancer truly resistant to 5-fluorouracil (5-FU). Van Cutsem, E., Cunningham, D., Ten Bokkel Huinink, W.W., Punt, C.J., Alexopoulos, C.G., Dirix, L., Symann, M., Blijham, G.H., Cholet, P., Fillet, G., Van Groeningen, C., Vannetzel, J.M., Levi, F., Panagos, G., Unger, C., Wils, J., Cote, C., Blanc, C., Hérait, P., Bleiberg, H. Eur. J. Cancer (1999) [Pubmed]
WikiGenes - Universities